The KEYNOTE-048 trial evaluated the use of ICI pembrolizumab, an anti-PD1 antibody, as a first-line treatment for recurrent or metastatic HNSCC considered incurable with local therapies [20]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.